Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: Evidence from animal and human studies

Reproductive Toxicology

Volumn 34, Issue 1, 2012, Pages 101-109

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

5 HT; Body weight; Depression; Fetal exposure; Overweight; Pregnancy; SSRI

Indexed keywords

FLUOXETINE; FLUVOXAMINE; NORADRENALIN UPTAKE INHIBITOR; NUCLEAR FACTOR Y; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; BEHAVIOR DISORDER; BODY WEIGHT; BODY WEIGHT DISORDER; BRAIN DEVELOPMENT; CHILD GROWTH; DEPRESSION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENERGY BALANCE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FETOTOXICITY; FOOD INTAKE; GROWTH DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MATERNAL STRESS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OBESITY; PRENATAL DEVELOPMENT; PRENATAL DRUG EXPOSURE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION;

ANIMALS; BODY WEIGHT; BRAIN; CHILD; CHILD DEVELOPMENT; EATING; FEMALE; FETAL DEVELOPMENT; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MATERNAL-FETAL EXCHANGE; PITUITARY-ADRENAL SYSTEM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

ANIMALIA;

EID: 84861703621     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.03.003     Document Type: Review

References (140)

1. Andrade S.E., Raebel M.A., Brown J., Lane K., Livingston J., Boudreau D., et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Ostet Gynecol 2008, 198(194):e1-e5.
2. Masand P.S., Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatry 1999, 7:69-84.
3. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmcokinet 1993, 24:203-220.
4. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Investigating outcomes following the use of SSRIs for treating depression in pregnancy: a focus on methodological issues. Drug Saf 2011, 34:1027-1048.
5. Ellfolk M., Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010, 30:249-260.
6. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
7. Ferreira E., Carceller A.M., Agogue C., Martin B.Z., St-Andre M., Francoeur D., et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007, 119:52-59.
8. Reis M., Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010, 40:1723-1733.
9. Levinson-Castiel R., Merlob P., Linder N., Sirota L., Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006, 160:173-176.
10. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194:961-966.
11. Lewis A.J., Galbally M., Opie G., Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010, 44:482-487.
12. Diav-Citrin O., Shechtman S., Weinbaum D., Wajnberg R., Avgil M., Di Gianantonio E., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008, 66:695-705.
13. Costei A.M., Kozer E., Ho T., Ito S., Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002, 156:1129-1132.
14. Galbally M., Lewis A.J., Lum J., Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009, 43:846-854.
15. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004, 158:312-316.
16. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63:898-906.
17. Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007, 16:1086-1094.
18. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors literature review and implications for clinical applications. JAMA 2005, 293:2372-2383.
19. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005, 365:482-487.
20. Laine K., Heikkinen T., Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60:720-726.
21. Popa D., Léna C., Alexandre C., Adrien J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 2008, 28:3546-3554.
22. Noorlander C.W., Ververs F.F.T., Nikkels P.G.J., van Echteld C.J.A., Visser G.H.A., Smidt M.P. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008, 3:e2782.
23. Oberlander T.F., Gingrich J.A., Ansorge M.S. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009, 86:672-677.
24. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
25. Maciag D., Simpson K.L., Coppinger D., Lu Y., Wang Y., Lin R.C.S., et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2005, 31:47-57.
26. Lisboa S.F.S., Oliveira P.E., Costa L.C., Venancio E.J., Moreira E.G. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007, 80:49-56.
27. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005, 19:623-633.
28. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-509.
29. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.R., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005, 25:595-604.
30. Whitaker-Azmitia P.M. Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001, 56:479-485.
31. Blundell J.E., Halford J.C.G. Serotonin and appetite regulation: implications for the pharmacological treatment of obesity. CNS Drugs 1998, 9:473-495.
32. Halford J.C., Harrold J.A., Lawton C.L., Blundell J.E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2005, 6:201-213.
33. Sargent B.J., Halford A.J. Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol 2011, 11:52-58.
34. Chambers C.D., Anderson P.O., Thomas R.G., Dick L.M., Felix R.J., Johnson K.A., et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999, 104:e61-e66.
35. Merlob P., Stahl B., Sulkes J. Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel. Eur J Pediatr 2004, 163:135-139.
36. Moretti M., Sharma A., Bar-Oz B., Koren G., Ito S. Fluoxetine and its effects on the nursing infant: A prospective cohort study. Clin Pharmacol Ther 1999, 65:141. [abstract].
37. Hendrick V., Smith L.M., Hwang S., Altshuler L.L., Haynes D. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry 2003, 64:410-412.
38. Hendrick V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003, 160:993-996.
39. Sundström E., Kölare S., Souverbie F., Samuelsson E.B., Pschera H., Lunell N.O., et al. Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res 1993, 75:1-12.
40. Mazer C., Muneyyirci J., Taheny K., Raio N., Borella A., Whitaker-Azmitia P. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 1997, 760:68-73.
41. Lauder J.M. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993, 16:233-240.
42. Whitaker-Azmitia P.M., Druse M., Walker P., Lauder J.M. Serotonin as a developmental signal. Behav Brain Res 1995, 73:19-29.
43. Blakely R.D., De Felice L.J., Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 1994, 196:263-281.
44. Homberg J.R., Schubert D., Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010, 31:60-65.
45. Goridis C., Rohrer H. Specification of catecholaminergic and serotonergic neurons. Nat Rev Neurosci 2002, 3:531-541.
46. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003, 4:1002-1012.
47. Woods S.C., Seeley R.J., Porte D., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 1998, 280:1378-1383.
48. üçeyler N., Schütt M., Palm F., Vogel C., Meier M., Schmitt A., et al. Lack of the serotonin transporter in mice reduces locomotor activity and leads to gender-dependent late onset obesity. Int J Obes 2010, 34:701-711.
49. Kalra S.P., Dube M.G., Pu S., Xu B., Horvath T.L., Kalra P.S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999, 20:68-99.
50. Collin M., Håkansson-Ovesjö M.L., Misane I., ögren S.O., Meister B. Decreased 5-HT transporter mRNA in neurons of the dorsal raphe nucleus and behavioral depression in the obese leptin-deficient ob/ob mouse. Brain Res Mol Brain Res 2000, 81:51-61.
51. Yadav V.K., Oury F., Suda N., Liu Z.W., Gao X.B., Confavreux C., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
52. Xu B., Goulding E.H., Zang K., Cepoi D., Cone R.D., Jones K.R., et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003, 6:736-742.
53. Blundell J. Is there a role for serotonin (5-hydroxytryptamine) in feeding. Int J Obes 1977, 1:15-42.
54. Saper C.B., Chou T.C., Elmquist J.K. The need to feed homeostatic and hedonic control of eating. Neuron 2002, 36:199-211.
55. Pôrto L.C.J., Sardinha F.L.C., Telles M.M., Guimarães R.B., Albuquerque K.T., Andrade I.S., et al. Impairment of the serotonergic control of feeding in adult female rats exposed to intra-uterine malnutrition. Br J Nutr 2009, 101:1255-1261.
56. Ribeiro E.B., Telles M.M., Oyama L.M., Silveira V.L.F., Nascimento C.M.O. Hypothalamic serotonin in the control of food intake: physiological interactions and effect of obesity. Focus on nutrition research 2005, 121-148. Nova Science Publishers, New York. T.P. Starks (Ed.).
57. Cripps R., Martin-gronert M., Ozanne S. Fetal and perinatal programming of appetite. Clin Sci 2005, 109:1-111.
58. Meguid M.M., Fetissov S.O., Varma M., Sato T., Zhang L., Laviano A., et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000, 16:843-857.
59. Blundell J.E. Serotonin and appetite. Neuropharmacology 1984, 23:1537-1551.
60. Blundell J.E. Serotonin manipulations and the structure of feeding behaviour. Appetite 1986, 7:S39-S56.
61. Shor-Posner G., Grinker J.A., Marinescu C., Brown O., Leibowitz S.F. Hypothalamic serotonin in the control of meal patterns and macronutrient selection. Brain Res Bull 1986, 17:663-671.
62. Weiss G.F., Rogacki N., Fueg A., Buchen D., Suh J.S., Wong D.T., et al. Effect of hypothalamic and peripheral fluoxetine injection on natural patterns of macronutrient intake in the rat. Psychopharmacology 1991, 105:467-476.
63. Leibowitz S.F., Alexander J.T. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998, 44:851-864.
64. Murphy D.L., Lesch K.P. Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 2008, 9:85-96.
65. Holmes A., Murphy D.L., Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry 2003, 54:953-959.
66. Heisler L.K., Chu H.M., Tecott L.H. Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci 2006, 861:74-78.
67. de Souza S.L., Orozco-Solis R., Grit I., de Castro R.M., Bolanos-Jimenez F. Perinatal protein restriction reduces the inhibitory action of serotonin on food intake. Eur J Neurosci 2008, 27:1400-1408.
68. Halford J.C.G., Blundell J.E. The 5-HT1B receptor agonist CP-94, 253 reduces food intake and preserves the behavioural satiety sequence. Physiol Behav 1996, 60:933-939.
69. Heisler L.K., Cowley M.A., Tecott L.H., Fan W., Low M.J., Smart J.L., et al. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297:609-611.
70. Heisler L.K., Jobst E.E., Sutton G.M., Zhou L., Borok E., Thornton-Jones Z., et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006, 51:239-249.
71. Dalton G.L., Lee M.D., Kennett G.A., Dourish C.T., Clifton P.G. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology 2006, 185:45-57.
72. Leibowitz S.F., Weiss G.F., Suh J.S. Medial hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behavior. Pharmacol Biochem Behav 1990, 37:735-742.
73. Clifton P., Kennett G. Monoamine receptors in the regulation of feeding behaviour and energy balance. CNS Neurol Disord Drug Targets 2006, 5:293-312.
74. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995, 374:542-546.
75. Lucas J.J., Yamamoto A., Scearce-Levie K., Saudou F., Hen R. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci 1998, 18:5537-5544.
76. Bouwknecht J.A., van der Gugten J., Hijzen T.H., Maes R.A.A., Hen R., Olivier B. Male and female 5-HT1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001, 74:507-516.
77. Collin M., Bäckberg M., önnestam K., Meister B. 5-HT1A receptor immunoreactivity in hypothalamic neurons involved in body weight control. Neuroreport 2002, 13:945-951.
78. Caldirola P. 5-HT6 receptor antagonism: a novel mechanism for the management of diabetes. SMI Conference on Obesity and Related Disorders, 2003 Feb 17-18 2003.
79. Pringle A., Jennings K.A., Line S., Bannerman D.M., Higgs S., Sharp T. Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine. Psychopharmacology 2008, 200:291-300.
80. Hainer V., Kabrnova K., Aldhoon B., Kunesova M., Wagenknecht M. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann N Y Acad Sci 2006, 1083:252-269.
81. Halford J.C.G., Harrold J.A., Boyland E.J., Lawton C.L., Blundell J.E. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27-55.
82. Miller K.J. Serotonin 5-HT2C receptor agonists: potential for the treatment of obesity. Mol Interv 2005, 5:282-291.
83. Lawton C., Wales J., Hill A., Blundell J. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res 1995, 3:345-356.
84. Nihalani N., Schwartz T.L., Siddiqui U.A., Megna J.L. Weight gain, obesity and psychotropic prescribing. J Obes 2011, 89:3-629.
85. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
86. Stock M. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997, 21:S25-S29.
87. Dobbing J., Sands J. Comparative aspects of the brain growth spurt. Early Hum Dev 1979, 3:79-83.
88. Cabrera T.M., Battaglia G. Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 1994, 269:637-645.
89. Lauder J.M., Liu J., Grayson D.R. In utero exposure to serotonergic drugs alters neonatal expression of 5-HT1A receptor transcripts: a quantitative RT-PCR study. Int J Dev Neurosci 2000, 18:171-176.
90. Cabrera-Vera T.M., Battaglia G. Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther 1998, 286:1474-1481.
91. Battaglia G. Criteria for assessing drug-induced biochemical alterations and degeneration of serotonergic neurons. Serotonin: from cell biology to pharmacology and therapeutics 1990, 651-660. Kluwer Academic Publishers, Dordrecht, The Netherlands. R. Paoletti, P.M. Vanhoutte, N. Brunello, F.M. Maggi (Eds.).
92. Cabrera-Vera T.M., Garcia F., Pinto W., Battaglia G. Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 1997, 280:138-145.
93. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997, 32:1-21.
94. Montero D., de Ceballos M.L., Del Rio J. Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci 1990, 46:1619-1626.
95. Coleman F.H., Christensen H.D., Gonzalez C.L., Rayburn W.F. Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil). Am J Obstet Gynecol 1999, 181:1166-1171.
96. Line S.J., Barkus C., Coyle C., Jennings K.A., Deacon R.M., Lesch K.P., et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol 2011, 21:108-116.
97. Homberg J.R., La Fleur S.E., Cuppen E. Serotonin transporter deficiency increases abdominal fat in female, but not male rats. Obesity 2010, 18:137-145.
98. Ren-Patterson R.F., Cochran L.W., Holmes A., Lesch K.P., Lu B., Murphy D.L. Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell Mol Neurobiol 2006, 26:753-778.
99. Li Q., Wichems C., Heils A., Lesch K.P., Murphy D.L. Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci 2000, 20:7888-7895.
100. Bouali S., Evrard A., Chastanet M., Lesch K.P., Hamon M., Adrien J. Sex hormone dependent desensitization of 5-HT1A autoreceptors in knockout mice deficient in the 5-HT transporter. Eur J Neurosci 2003, 18:2203-2212.
101. Pedersen L.H., Henriksen T.B., Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010, 125:e600-e608.
102. Wrotniak B.H., Epstein L.H., Dorn J.M., Jones K.E., Kondilis V.A. The relationship between motor proficiency and physical activity in children. Pediatrics 2006, 118:e1758-e1765.
103. Cosgrove K.P., Mazure C.M., Staley J.K. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry 2007, 62:847-855.
104. Jovanovic H., Lundberg J., Karlsson P., Cerin å., Saijo T., Varrone A., et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 2008, 39:1408-1419.
105. Deussing J. Animal models of depression. Drug Discov Today Dis Models 2007, 3:375-383.
106. Pariante C., Lightman S. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31:464-468.
107. Hayashi A., Nagaoka M., Yamada K., Ichitani Y., Miake Y., Okado N. Maternal stress induces synaptic loss and developmental disabilities of offspring. Int J Dev Neurosci 1998, 16:209-216.
108. Peters D.A.V. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress influences brain development. Pharmacol Biochem Behav 1990, 35:943-947.
109. Peters D.A. Prenatal stress: effect on development of rat brain serotonergic neurons. Pharmacol Biochem Behav 1986, 24:1377-1382.
110. Matthews S. Early programming of the hypothalamo-pituitary-adrenal axis. Trends Endocrinol Metab 2002, 13:373-380.
111. Talge N., Neal C., Glover V. Antenatal maternal stress and long term effects on child neurodevelopment: how and why. J Child Psychol Psychiatry 2007, 48:245-261.
112. Cottrell E.C., Seckl J.R. Prenatal stress, glucocorticoids and the programming of adult disease. Front Behav Neurosci 2009, 2009.
113. Bjorntorp P. Neuroendocrine factors in obesity. J Endocrinol 1997, 155:193-195.
114. Drake A., Tang J., Nyirenda M. Mechanisms underlying the role of glucocorticoids in the early life programming of adult disease. Clin Sci 2007, 113:219-232.
115. Oberlander T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008, 84:689-697.
116. Andrews M.H., Matthews S.G. Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress 2004, 7:15-27.
117. Szuran T.F., Plika V., Pokorny J., Welzl H. Prenatal stress in rats: effects on plasma corticosterone, hippocampal glucocorticoid receptors, and maze performance. Physiol Behav 2000, 71:353-362.
118. Weinstock M., Matlina E., Maor G.I., Rosen H., McEwen B.S. Prenatal stress selectively alters the reactivity of the hypothalamic-pituitary adrenal system in the female rat. Brain Res 1992, 595:195-200.
119. McCormick C.M., Smythe J.W., Sharma S., Meaney M.J. Sex-specific effects of prenatal stress on hypothalamic-pituitary-adrenal responses to stress and brain glucocorticoid receptor density in adult rats. Brain Res Dev Brain Res 1995, 84:55-61.
120. Li J., Olsen J., Vestergaard M., Obel C., Baker J.L., Sorensen T.I.A. Prenatal stress exposure related to maternal bereavement and risk of childhood overweight. PLoS ONE 2010, 5:e11896.
121. Ishiwata H., Shiga T., Okado N. Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stress-induced brain dysfunction. Neuroscience 2005, 133:893-901.
122. Morrison J.L., Riggs K.W., Chien C., Gruber N., McMillen I.C., Rurak D.W. Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res 2004, 56:40-46.
123. Jiang X., Wang J., Luo T., Li Q. Impaired hypothalamic-pituitary-adrenal axis and its feedback regulation in serotonin transporter knockout mice. Psychoneuroendocrinology 2009, 34:317-331.
124. Ertel K.A., Koenen K.C., Rich-Edwards J.W., Gillman M.W., Myer L. Maternal depressive symptoms not associated with reduced height in young children in a US prospective cohort study. PLoS ONE 2010, 5:e13656.
125. Halligan S.L., Herbert J., Goodyer I.M., Murray L. Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry 2004, 55:376-381.
126. Bugental D.B., Martorell G.A., Barraza V. The hormonal costs of subtle forms of infant maltreatment. Horm Behav 2003, 43:237-244.
127. Hurley K.M., Black M.M., Papas M.A., Caufield L.E. Maternal symptoms of stress, depression, and anxiety are related to nonresponsive feeding styles in a statewide sample of WIC participants. J Nutr 2008, 138:799-805.
128. Ajslev T.A., Andersen C.S., Ingstrup K.G., Nohr E.A., Sørensen T.I.A. Maternal postpartum distress and childhood overweight. PLoS ONE 2010, 5:e11136.
129. Nulman I., Rovet J., Stewart D.E., Wolpin J., Gardner H.A., Theis J.G.W., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336:258-262.
130. Nulman I., Rovet J., Stewart D.E., Wolpin J., Pace-Asciak P., Shuhaiber S., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002, 159:1889-1895.
131. Heikkinen T., Ekblad U., Kero P., Ekblad S., Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002, 72:184-191.
132. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408.
133. Heikkinen T., Ekblad U., Palo P., Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003, 73:330-337.
134. Qu Y., Villacreses N., Murphy D.L., Rapoport S.I. 5-HT 2A/2C receptor signaling via phospholipase A 2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology 2005, 180:12-20.
135. Moya P., Fox M., Jensen C., Laporte J., French H., Wendland J., et al. Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol 2011, 11:3.
136. Hutson P., Dourish C., Curzon G. Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors. Eur J Pharmacol 1988, 150:361-366.
137. Li Q., Wichems C.H., Ma L., Van de Kar L.D., Garcia F., Murphy D.L. Brain region specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 2003, 84:1256-1265.
138. Hansen H.H., Mikkelsen J.D. Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 1998, 352:307-315.
139. Kim D.K., Tolliver T.J., Huang S.J., Martin B.J., Andrews A.M., Wichems C., et al. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 2005, 49:798-810.
140. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (Ecstasy) in serotonin transporter-deficient mice. Mol Pharmacol 1998, 53:649-655.